<DOC>
	<DOCNO>NCT02710604</DOCNO>
	<brief_summary>This phase 2a study evaluate safety tolerability multiple oral dos CMX157 increase dose level .</brief_summary>
	<brief_title>Phase 2 , Multiple Ascending Dose Proof Concept Study</brief_title>
	<detailed_description>This phase 2a study evaluate safety tolerability multiple oral dos CMX157 increase dose level hepatitis B virus ( HBV ) infect subject .</detailed_description>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Capable give write informed consent . Capable completing study requirement . Chronic hepatitis B positive . HBV treatment na√Øve . Positive result HCV ( hepatitis C virus ) , HDV ( hepatitis D virus ) HIV ( human immunodeficiency virus ) . History medical condition could impact patient safety . Current past abuse alcohol illicit drug . Abnormal laboratory value ECG . Pregnant breastfeeding . Clinical , histologic laboratory evidence significant liver fibrosis cirrhosis . Systemic immunosuppression . Received investigational drug investigational vaccine within 90 day prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>chronic hepatitis B ( CHB )</keyword>
</DOC>